Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

By
In News
Posted

Sentien to Present SBI-101 Clinical Data in AKI at 2020 ASGCT Annual Meeting that Supports Expansion to COVID-19

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Sentien to Present SBI-101 Clinical Data in AKI at 2020 American Society of Gene & Cell Therapy Annual Meeting that Supports Expansion to COVID-19

Sentien’s R&D team will present platform development and clinical data at the American Society of Gene & Cell Therapy Annual Meeting during virtual poster sessions.

Sentien’s SBI-101 clinical data in AKI patients shows immunomodulatory effects consistent with our therapeutic hypothesis and also applicable to COVID-19 patients.

Clinical Evidence for Immune Reprogramming with Extracorporeal Mesenchymal Stromal Cell Therapy

Ex-Vivo Cell Therapy Platform for Immune Reprogramming in Autoimmunity

Sentien Co-Founder Dr. Biju Parekkadan Gives a Live Interview at World Advanced Therapies & Regenerative Medicine Congress

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Sentien Co-Founder Dr. Biju Parekkadan Gives a Live Interview at World Advanced Therapies & Regenerative Medicine Congress

Watch Dr. Parekkadan’s interview at the World Advanced Therapies & Regenerative Medicine Congress in London here!
SEE VIDEO >

Cell Trials Data Selects Sentien’s Ph 1/2 Study of SBI-101 for AKI as Its Featured Advanced Cell Therapy Trial

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Cell Trials Data Selects Sentien’s Ph 1/2 Study of SBI-101 for AKI as Its Featured Advanced Cell Therapy Trial

In September, our clinical trial was selected by Cell Trials Data as its Featured Advanced Cell Therapy Trial.
READ MORE >

Sentien Announces Open Enrollment in Phase 1/2 Trial of SBI-101 for Patients with Acute Kidney Injury

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Sentien Announces Open Enrollment in Phase 1/2 Trial of SBI-101 for Patients with Acute Kidney Injury

Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, announced that it has opened enrollment in its Phase 1/2 trial of SBI-101 for adult patients with acute kidney injury (AKI). This trial is Sentien’s first clinical program.
READ MORE >

Sentien Biotechnologies Featured in FierceBiotech

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Sentien Biotechnologies Featured in FierceBiotech

Sentien Biotechnologies was featured in FierceBiotech on April 17, 2017.  In the article, Sentien co-founder Biju Parekkadan discusses the company’s recent $12M Series A round, the technology behind Sentien’s lead product, and the upcoming clinical trial of the product in acute kidney injury patients.
READ MORE >

Sentien Announces Active IND for SBI-101 in Patients with Acute Kidney Injury

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Sentien Announces Active IND for SBI-101 in Patients with Acute Kidney Injury

At the Stem Cell Summit on 4/7, Sentien CEO Brian Miller announced that the company’s investigational new drug (IND) application for SBI-101 for the treatment of adult patients with acute kidney injury (AKI) is now active. The IND, which the company has filed in the United States with the Food and Drug Administration, enables Sentien to initiate a multi-center, Phase 1/2 trial to evaluate the administration of SBI-101 in this patient population. The trial will be the first clinical program for Sentien Biotechnologies. Read More >

Load More